Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
← catalyst calendarNCT07446582 · readout in 17 d
Sponsored by AI-Spectral (industry) · MDAI — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-01 | actual | When the study began enrolling |
| Primary completion | 2026-09-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Age-Related (Dry) Macular Degeneration
Intervention
- Device: Retina imaging device (MSI-120) and AI (DeepMSI AI)
Primary outcome
what the primary-completion date above is the date OFAssessment of equivalency in sensitivity and specificity of the DeepMSI AI system compared with experienced clinicians for detection of AMD biomarkers.
measured through study completion, an average of 6 months
Permalink · MDAI's whole pipeline · Catalyst calendar · Every registered study · What changed